Quantitative Radiomic Features As New Biomarkers for Alzheimer's Disease: an Amyloid PET Study.

Yanhui Ding,Kun Zhao,Tongtong Che,Kai Du,Hongzan Sun,Shu Liu,Yuanjie Zheng,Shuyu Li,Bing Liu,Yong Liu
DOI: https://doi.org/10.1093/cercor/bhab061
IF: 4.861
2021-01-01
Cerebral Cortex
Abstract:Growing evidence indicates that amyloid-beta (A beta) accumulation is one of the most common neurobiological biomarkers in Alzheimer's disease (AD). The primary aim of this study was to explore whether the radiomic features of A beta positron emission tomography (PET) images are used as predictors and provide a neurobiological foundation for AD. The radiomics features of A beta PET imaging of each brain region of the Brainnetome Atlas were computed for classification and prediction using a support vector machine model. The results showed that the area under the receiver operating characteristic curve (AUC) was 0.93 for distinguishing AD (N=291) from normal control (NC; N= 334). Additionally, the AUC was 0.83 for the prediction of mild cognitive impairment (MCI) converting (N=88) (vs. no conversion, N=100) to AD. In the MCI and AD groups, the systemic analysis demonstrated that the classification outputs were significantly associated with clinical measures (apolipoprotein E genotype, polygenic risk scores, polygenic hazard scores, cerebrospinal fluid A beta, and Tau, cognitive ability score, the conversion time for progressive MCI subjects and cognitive changes). These findings provide evidence that the radiomic features of A beta PET images can serve as new biomarkers for clinical applications in AD/MCI, further providing evidence for predicting whether MCI subjects will convert to AD.
What problem does this paper attempt to address?